A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Clinical trial NCT04400695 · UNKNOWN
Trial details
- NCT number
- NCT04400695
- Sponsor
- RemeGen Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-29
- Primary completion
- 2024-06-30
- Enrollment
- 366
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.